Proteasome Inhibitors: Structure and Function

le Nunes, Ana T., Annunziata, Christina M.
Foilsithe in Semin Oncol (2018)

NF-κB Signaling in Ovarian Cancer

le Harrington, Brittney S., Annunziata, Christina M.
Foilsithe in Cancers (Basel) (2019)

PARP as a novel therapeutic target in cancer

le Annunziata, Christina M., O’Shaughnessy, Joyce
Foilsithe 2010

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer

le Annunziata, Christina M, Bates, Susan E
Foilsithe 2010

Editorial: Inhibiting PARP as a Strategic Target in Cancer

le Zorn, Kristin K., Annunziata, Christina M.
Foilsithe in Front Oncol (2016)

Clinical Trials in Gynecologic Oncology: Past, Present, and Future

le Annunziata, Christina M., Kohn, Elise C.
Foilsithe in Gynecol Oncol (2017)

Targeting the Proteasome With Bortezomib in Multiple Myeloma: Update on Therapeutic Benefit as an Upfront Single Agent, Induction Regimen for Stem-Cell Transplantation and as Maint...

le Driscoll, James J., Burris, Jason, Annunziata, Christina M.
Foilsithe 2012

Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer

le House, Carrie Danielle, Hernandez, Lidia, Annunziata, Christina Messineo
Foilsithe 2014

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

le House, Carrie D., Hernandez, Lidia, Annunziata, Christina M.
Foilsithe in J Vis Exp (2015)

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells

le Kim, Marianne K, James, Jana, Annunziata, Christina M
Foilsithe in BMC Cancer (2015)

Driving Immune Responses in the Ovarian Tumor Microenvironment

le Ning, Franklin, Cole, Christopher B., Annunziata, Christina M.
Foilsithe in Front Oncol (2021)

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment

le Zeligs, Kristen P., Neuman, Monica K., Annunziata, Christina M.
Foilsithe in Clin Cancer Res (2016)

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma

le Pongas, Georgios N., Annunziata, Christina M., Staudt, Louis M.
Foilsithe in Oncotarget (2017)

Monocyte and interferon based therapy for the treatment of ovarian cancer

le Green, Daniel S., Nunes, Ana T., Annunziata, Christina M., Zoon, Kathryn C.
Foilsithe in Cytokine Growth Factor Rev (2016)

Proteomics as a Tool for Biomarker Discovery

le Kohn, Elise C., Azad, Nilofer, Annunziata, Christina, Dhamoon, Amit S., Whiteley, Gordon
Foilsithe 2007

Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via Caspase 8-independent mechanism

le Hernandez, Lidia F., Dull, Angie B., Korrapati, Soumya, Annunziata, Christina M.
Foilsithe in Cell Death Discov (2021)

Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21

le Kim, Marianne K., Min, Dong J., Wright, George, Goldlust, Ian, Annunziata, Christina M.
Foilsithe in Oncotarget (2014)

Activation of NF-κB signaling by IKKβ increases aggressiveness of ovarian cancer

le Hernandez, Lídia, Hsu, Sarah, Davidson, Ben, Birrer, Michael J., Kohn, Elise C., Annunziata, Christina M.
Foilsithe 2010

IKKε coordinates invasion and metastasis of ovarian cancer

le Hsu, Sarah, Kim, Marianne, Hernandez, Lidia, Grajales, Valentina, Noonan, Anne, Anver, Miriam, Davidson, Ben, Annunziata, Christina M.
Foilsithe 2012

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells

le Fantini, Massimo, David, Justin M., Wong, Hing C., Annunziata, Christina M., Arlen, Philip M., Tsang, Kwong Y.
Foilsithe in Cancer Biother Radiopharm (2019)